FindTrial
Sign In

INNO-206

DRUG4 trials

Sponsors

CytRx, ImmunityBio, Inc.

Conditions

Locally Advanced Soft Tissue SarcomaMalignant Solid TumourMetastatic Soft Tissue SarcomaPancreatic Ductal AdenocarcinomaSmall Cell Lung CancerUnresectable Soft Tissue Sarcoma

Phase 1

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
CompletedNCT01337505
ImmunityBio, Inc.Malignant Solid Tumour
Start: 2011-04-30End: 2012-12-31Updated: 2022-02-10

Phase 2

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
WithdrawnNCT00472771
CytRxSmall Cell Lung Cancer
Start: 2008-05-31End: 2008-11-30Updated: 2012-02-09
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
CompletedNCT01514188
ImmunityBio, Inc.Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Start: 2012-01-11End: 2014-12-15Updated: 2024-05-29
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
CompletedNCT01580397
ImmunityBio, Inc.Pancreatic Ductal Adenocarcinoma
Start: 2012-05-16End: 2013-07-02Updated: 2024-06-06

Related Papers

Cardiac safety of aldoxorubicin compared to doxorubicin: Integrated results from two randomized studies in advanced soft tissue sarcoma.
Journal of Clinical Oncology2026-05-27
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma
JAMA Oncology2015-09-17105 citations
Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas.
Journal of Clinical Oncology2014-05-207 citations